Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Nivolumab and Lirilumab in Cisplatin-Ineligible MIBC
NCT03532451Phase 1Completed
- Sponsor
- PrECOG
- Start
- Mar 2019
- Primary completion
- Nov 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of lirilumab in muscle-invasive bladder cancer (MIBC) (2 arms), sponsored by PrECOG. Primary endpoint: Grade 3 or Higher Treatment Related Adverse Events at 16 months. Started Mar 2019; status: completed.
02
Drugs
lirilumab
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT03532451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03532451.